Insight Molecular Diagnostics
IMDX
86 hedge funds and large institutions have $81.2M invested in Insight Molecular Diagnostics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 31 reducing their positions, and 12 closing their positions.
1,059% more call options, than puts
Call options by funds: $255K | Put options by funds: $22K
0.06% less ownership
Funds ownership: 3.01% → 2.95% (-0.06%)
2% less funds holding
Funds holding: 88 → 86 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
32% less capital invested
Capital invested by funds: $120M → $81.2M (-$38.7M)
45% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 31
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$552K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$328K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$145K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$75.2K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
+$51.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$818K |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$430K |
| 3 |
Two Sigma Investments
New York
|
-$352K |
| 4 |
Millennium Management
New York
|
-$306K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
-$160K |
IMDX Hedge Fund Activity: Q1 2022 in Review
86 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2022, worth a combined $81.2M — down 32% from $120M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of IMDX and 10 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 17 added.
The largest buyer was Defender Capital, adding an estimated $552K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $818K sold.
- 86 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2022, down from 88 in Q4 2021.
- Funds reported $81.2M of Insight Molecular Diagnostics stock for Q1 2022, down 32% quarter-over-quarter.
- 10 funds opened new Insight Molecular Diagnostics positions in Q1 2022 and 12 closed out, a net change of -2 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2022 was Defender Capital, an estimated $552K added.
- The largest Insight Molecular Diagnostics seller in Q1 2022 was Two Sigma Advisers, an estimated $818K sold.
Based on aggregated 13F filings for Q1 2022.